US Opens Germany Tariff Probe Over Underpayment for Innovative Drugs
The US launched a Section 301 investigation against Germany over what Trade Representative Jamieson Greer called 'persistent underpayment for innovative pharmaceutical products.' The probe will determine whether those practices are unreasonable or discriminatory.
The move sets the stage for potential retaliatory levies on German goods if the US decides Germany's treatment of those products warrants action.
From the sources (4 posts)
@firstsquawkUSTR GREER LAUNCHES SECTION 301 INVESTIGATION AGAINST GERMANY TO DETERMINE WHETHER PERSISTENT UNDERPAYMENT FOR INNOVATIVE PHARMACEUTICAL PRODUCTS IS UNREASONABLE OR DISCRIMINATORY.
@firstsquawkThe U.S. has initiated a Section 301 trade probe against Germany, according to a statement from Trade Representative Jamieson Greer.
@businessThe US launched a fresh tariff investigation into Germany over what it called “persistent underpayment for innovative pharmaceutical products,” setting the stage for levies on its goods in retaliation
@businessBREAKING: The US launches a fresh tariff investigation into Germany over what it called “persistent underpayment for innovative pharmaceutical products"